Request Demo
Last update 05 Mar 2026
Autologous NK cell(Guangzhou DoublleBioproduct)
Last update 05 Mar 2026
Overview
Basic Info
Drug Type Natural Killer Cell Therapies |
Synonyms E10H |
Target- |
Action- |
Mechanism Cell replacements |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
3
Clinical Trials associated with Autologous NK cell(Guangzhou DoublleBioproduct)CTR20222083
评估 E10H 在晚期消化道癌患者中安全性与耐受性的 I 期临床研究
[Translation] Phase I clinical study to evaluate the safety and tolerability of E10H in patients with advanced gastrointestinal cancer
JPRN-UMIN000014072
A phase I/II clinical study of expanded autologous NK cell combined with rituximab-based chemotherapy in patients with CD20 positive B-cell lymphoma - A phase I/II clinical study of expanded autologous NK cell combined with rituximab-based chemotherapy in patients with B-cell lymphoma
CTR20260775
一项评价E10H联合IgG1抗体和化疗一线治疗晚期消化道癌患者有效性和安全性的随机、开放、多中心的II期临床研究
[Translation] A randomized, open-label, multicenter phase II clinical trial evaluating the efficacy and safety of E10H combined with IgG1 antibody and chemotherapy as first-line treatment for patients with advanced gastrointestinal cancer.
100 Clinical Results associated with Autologous NK cell(Guangzhou DoublleBioproduct)
Login to view more data
100 Translational Medicine associated with Autologous NK cell(Guangzhou DoublleBioproduct)
Login to view more data
100 Patents (Medical) associated with Autologous NK cell(Guangzhou DoublleBioproduct)
Login to view more data
100 Deals associated with Autologous NK cell(Guangzhou DoublleBioproduct)
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| BRAF Mutation colorectal cancers | Phase 2 | China | 04 Mar 2026 | |
| Colorectal Cancer | Phase 2 | China | 04 Mar 2026 | |
| HER2 positive Gastroesophageal Junction Adenocarcinoma | Phase 2 | China | 04 Mar 2026 | |
| HER2 Positive Stomach Adenocarcinoma | Phase 2 | China | 04 Mar 2026 | |
| Metastatic Colorectal Carcinoma | Phase 2 | China | 04 Mar 2026 | |
| Metastatic Gastric Carcinoma | Phase 2 | China | 04 Mar 2026 | |
| Stomach Cancer | Phase 2 | China | 04 Mar 2026 | |
| Advanced gastric carcinoma | Phase 1 | China | 18 Nov 2022 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free